|
M/F
|
27/34
|
26/46
|
n.s.
|
|
Median age (years)
|
58.0 (23–84)
|
55.5 (20–87)
|
n.s.
|
|
Mean WBC (109/l)
|
7.5
|
8.4
|
p = 0.001
|
|
Mean Hb (g/dl)
|
14.1
|
14.3
|
n.s.
|
|
Mean PLT (109/l)
|
751
|
798
|
n.s.
|
|
Increased LDH (%)
|
17/45 (37.7%)
|
18/50 (36.0%)
|
n.s.
|
|
Splenomegaly (%)
|
12 (19%)
|
18 (25%)
|
n.s.
|
|
Mean semiquantitative score for granulopoiesis
|
0.15
|
1.02
|
p = 0.001
|
|
JAK2V617F-positive (%)
|
11 (33%)
|
23 (54%)
|
n.s.
|
|
History of thrombosis (%)
|
5 (8%)
|
16 (22%)
|
p = 0.032
|
|
Thrombosis at diagnosis (%)
|
1 (1.6%)
|
11 (15.2%)
|
p = 0.006
|
|
Thrombotic events during follow up (%)
|
7 (11.4%)
|
11 (15.2%)
|
n.s.
|
|
Progression to overt MF (%)
|
1 (1.6%)
|
3 (4.1%)
|
n.s.
|
|
Dead/alive
|
2/59
|
8/64
|
n.s.
|
|
Conventional Risk (Low/High)
|
35/26
|
30/42
|
n.s.
|
|
Cytoreductive therapy (%)
|
51 (83%)
|
64 (88%)
|
n.s.
|
